Skip to main content

Advertisement

SpringerLink
Log in

The Impact of Transgenic IGF-IR Overexpression on Mammary Development and Tumorigenesis

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

Insulin-like growth factor-I and -II (IGF-I and IGF-II) and/or the type I insulin-like growth factor receptor (IGF-IR) have been implicated in a number of human tumors including breast cancer. However, despite being implicated in breast cancer for approximately 25 years and given that transgenic technology has been available for about the same period of time, it is surprising that transgenic mice overexpressing the IGF-IR in the mammary gland have only recently been characterized. This review will describe the effects of IGF-IR overexpression on mammary ductal morphogenesis and mammary tumorigenesis in the two available transgenic models.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CD8-IGFIR:

transgenic mice expressing constitutively active IGF-IR in mammary epithelial cells

EMT:

epithelial to mesenchymal transition

ER:

estrogen receptor

IGF:

insulin-like growth factor

IGFBP:

insulin-like growth factor binding protein

IGF-IR:

type I insulin-like growth factor receptor

IRS:

insulin receptor substrate

MMTV:

mammary tumor virus promoter

MTB-IGFIR:

bi-transgenic mice expressing the full length human IGF-IR cDNA in the mammary epithelial cells in a doxycycline-inducible manner

PR:

progesterone receptor

RM11A:

primary mammary tumor cells derived from a MTB-IGFIR mammary tumor

rtTA:

reverse tetracycline transactivator

TEB:

terminal end bud

TRE:

tetracycline responsive element

WAP:

whey acid protein

References

  1. Furstenberger G, Morant R, Senn HJ. Insulin-like growth factors and breast cancer. Onkologie 2003;26:290–4. doi:10.1159/000071627.

    Article  PubMed  CAS  Google Scholar 

  2. Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18:67–79. doi:10.1016/S1521-690X(03)00045-9.

    Article  PubMed  CAS  Google Scholar 

  3. Koda M, Przystupa W, Jarzabek K, Wincewicz A, Kanczuga-Koda L, Tomaszewski J, et al. Expression of insulin-like growth factor-I receptor, estrogen receptor alpha, Bcl-2 and Bax proteins in human breast cancer. Oncol Rep. 2005;14:93–8.

    PubMed  CAS  Google Scholar 

  4. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett. 2007;257:236–43.

    Article  PubMed  CAS  Google Scholar 

  5. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res. 2004;64:286–91. doi:10.1158/0008-5472.CAN-03-1242.

    Article  PubMed  CAS  Google Scholar 

  6. Surmacz E, Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat. 1998;47:255–67. doi:10.1023/A:1005907101686.

    Article  PubMed  CAS  Google Scholar 

  7. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type I IGF receptor (Igf1r). Cell 1993;75:59–72.

    PubMed  CAS  Google Scholar 

  8. Bonnette SG, Hadsell DL. Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 2001;142:4937–45. doi:10.1210/en.142.11.4937.

    Article  PubMed  CAS  Google Scholar 

  9. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984;38:627–37. doi:10.1016/0092-8674(84)90257-5.

    Article  PubMed  CAS  Google Scholar 

  10. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105–15. doi:10.1016/0092-8674(88)90184-5.

    Article  PubMed  CAS  Google Scholar 

  11. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669–71. doi:10.1038/369669a0.

    Article  PubMed  CAS  Google Scholar 

  12. LeRoith D, Neuenschwander S, Wood TL, Henninghausen L. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 inhibit involution of the mammary gland following lactation: studies in transgenic mice. Prog Growth Factor Res. 1995;6:433–6. doi:10.1016/0955-2235(96)00009-9.

    Article  PubMed  CAS  Google Scholar 

  13. Moorehead RA, Fata JE, Johnson MB, Khokha R. Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ. 2001;8:16–29. doi:10.1038/sj.cdd.4400762.

    Article  PubMed  CAS  Google Scholar 

  14. Pravtcheva DD, Wise TL. Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool. 1998;281:43–57. doi:10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.0.CO;2-C.

    Article  PubMed  CAS  Google Scholar 

  15. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer. 1995;72:1189–93.

    PubMed  CAS  Google Scholar 

  16. Hadsell DL, Greenberg NM, Fligger JM, Baumrucker CR, Rosen JM. Targeted expression of des(1-3) human insulin-like growth factor I (IGF-I) in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1997;137:321–30. doi:10.1210/en.137.1.321.

    Article  Google Scholar 

  17. Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Henninghausen L. Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest. 1996;97:2225–32. doi:10.1172/JCI118663.

    Article  PubMed  CAS  Google Scholar 

  18. de Ostrovich KK, Lambertz I, Colby JK, Tian J, Rundhaug JE, Johnston D, et al. Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am J Pathol. 2008;173:824–34. doi:10.2353/ajpath.2008.071005.

    Article  PubMed  Google Scholar 

  19. Hadsell DL, Torres DT, Lawrence NA, George J, Parlow AF, Lee AV, et al. Overexpression of des(1-3) insulin-like growth factor 1 in the mammary glands of transgenic mice delays the loss of milk production with prolonged lactation. Biol Reprod. 2005;73:1116–25. doi:10.1095/biolreprod.105.043992.

    Article  PubMed  CAS  Google Scholar 

  20. Su HY, Cheng WT. Increased milk yield in transgenic mice expressing insulin-like growth factor 1. Anim Biotechnol. 2004;15:9–19. doi:10.1081/ABIO-120027521.

    Article  PubMed  CAS  Google Scholar 

  21. Hadsell DL, Alexeenko T, Klimentidis Y, Torres D, Lee AV. Inability of overexpressed des(1-3)human insulin-like growth factor I (IGF-I) to inhibit forced mammary gland involution is associated with decreased expression of IGF signaling molecules. Endocrinology 2001;142:1479–88. doi:10.1210/en.142.4.1479.

    Article  PubMed  CAS  Google Scholar 

  22. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 2000;19:889–98. doi:10.1038/sj.onc.1203386.

    Article  PubMed  CAS  Google Scholar 

  23. Burrin DG, Fiorotto ML, Hadsell DL. Transgenic hypersecretion of des(1-3) human insulin-like growth factor I in mouse milk has limited effects on the gastrointestinal tract in suckling pups. J Nutr. 1999;129:51–6.

    PubMed  CAS  Google Scholar 

  24. Weber MS, Boyle PL, Corl BA, Wong EA, Gwazdauskas FC, Akers RM. Expression of ovine insulin-like growth factor-1 (IGF-1) stimulates alveolar bud development in mammary glands of transgenic mice. Endocrine 1998;8:251–9. doi:10.1385/ENDO:8:3:251.

    Article  PubMed  CAS  Google Scholar 

  25. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 2005;65:3781–7. doi:10.1158/0008-5472.CAN-04-4602.

    Article  PubMed  CAS  Google Scholar 

  26. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 2002;16:283–92. doi:10.1096/fj.01-0551com.

    Article  PubMed  CAS  Google Scholar 

  27. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636–44. doi:10.1038/sj.onc.1209955.

    Article  PubMed  CAS  Google Scholar 

  28. Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF. ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA. 2004;101:17138–43. doi:10.1073/pnas.0407057101.

    Article  PubMed  CAS  Google Scholar 

  29. Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G. Ductal growth is impeded in mammary glands of C-neu transgenic mice. Oncogene 2000;19:5982–7. doi:10.1038/sj.onc.1203964.

    Article  PubMed  CAS  Google Scholar 

  30. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9:493–505. doi:10.1038/ncb1567.

    Article  PubMed  CAS  Google Scholar 

  31. Vargo-Gogola T, Heckman BM, Gunther EJ, Chodosh LA, Rosen JM. P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland. Mol Endocrinol. 2006;20:1391–405. doi:10.1210/me.2005-0426.

    Article  PubMed  CAS  Google Scholar 

  32. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol. 2007;27:3165–75. doi:10.1128/MCB.01315-06.

    Article  PubMed  CAS  Google Scholar 

  33. Jones RA, Campbell CI, Petrik JJ, Moorehead RA. Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor. Mol Cancer Res. 2008;6:819–28. doi:10.1158/1541-7786.MCR-07-2157.

    Article  PubMed  CAS  Google Scholar 

  34. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 1999;18:2149–64. doi:10.1093/emboj/18.8.2149.

    Article  PubMed  CAS  Google Scholar 

  35. Rubini M, Hongo A, D’Ambrosio C, Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res. 1997;230:284–92. doi:10.1006/excr.1996.3430.

    Article  PubMed  CAS  Google Scholar 

  36. Resnik JL, Reichart DB, Huey K, Webster NJG, Seely BL. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 1998;58:1159–64.

    PubMed  CAS  Google Scholar 

  37. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle. 2007;6:705–13.

    PubMed  CAS  Google Scholar 

  38. Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol. 2006;26:9302–14. doi:10.1128/MCB.00260-06.

    Article  PubMed  CAS  Google Scholar 

  39. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. Reversibility and recurrence of IGF-IR-induced mammary tumors. Mol Cell Biol. 2008; submitted.

  40. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2:451–61. doi:10.1016/S1535-6108(02)00212-X.

    Article  PubMed  CAS  Google Scholar 

  41. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005;8:197–209. doi:10.1016/j.ccr.2005.07.009.

    Article  PubMed  CAS  Google Scholar 

  42. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6:577–86. doi:10.1016/j.ccr.2004.10.013.

    Article  PubMed  CAS  Google Scholar 

  43. Jang JW, Boxer RB, Chodosh LA. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol. 2006;26:8109–21. doi:10.1128/MCB.00404-06.

    Article  PubMed  CAS  Google Scholar 

  44. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 2008;19:294–308. doi:10.1016/j.semcdb.2008.02.001.

    Article  PubMed  CAS  Google Scholar 

  45. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54. doi:10.1038/nrc822.

    Article  PubMed  CAS  Google Scholar 

  46. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–83. doi:10.1002/jcp.21223.

    Article  PubMed  CAS  Google Scholar 

  47. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20:4942–50. doi:10.1038/sj.onc.1204660.

    Article  PubMed  CAS  Google Scholar 

  48. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005;171:1023–34. doi:10.1083/jcb.200505087.

    Article  PubMed  CAS  Google Scholar 

  49. Yanochko GM, Eckhart W. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res. 2006;8:R18. doi:10.1186/bcr1392.

    Article  PubMed  Google Scholar 

  50. Russo J, Moral R, Balogh GA, Mailo D, Russo IH. The protective role of pregnancy in breast cancer. Breast Cancer Res. 2005;7:131–42. doi:10.1186/bcr1029.

    Article  PubMed  Google Scholar 

  51. McGregor H, Land CE, Choi K, Tokuoka S, Liu PI, Wakabayashi T, et al. Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950-69. J Natl Cancer Inst. 1977;59:799–811.

    PubMed  CAS  Google Scholar 

  52. Yang J, Yoshizawa K, Nandi S, Tsubura A. Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. Carcinogenesis 1999;20:623–8. doi:10.1093/carcin/20.4.623.

    Article  PubMed  Google Scholar 

  53. Russo IH, Russo J. Mammary carcinogenesis: role of differentiation in tumor initiation. Surg Pathol. 1994;5:307–26.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada, N1G2W1

    Robert A. Jones & Roger A. Moorehead

Authors
  1. Robert A. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger A. Moorehead
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger A. Moorehead.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, R.A., Moorehead, R.A. The Impact of Transgenic IGF-IR Overexpression on Mammary Development and Tumorigenesis. J Mammary Gland Biol Neoplasia 13, 407–413 (2008). https://doi.org/10.1007/s10911-008-9097-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10911-008-9097-1

Keywords

Search

Navigation